FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W59652332> ?p ?o ?g. }

• W59652332 endingPage "33S" @default.
• W59652332 startingPage "27S" @default.
• W59652332 abstract "Antiplatelet therapy plays a pivotal role in the treatment of patients with acute coronary syndromes (ACS), inducing a significant reduction of ischemic events. Aspirin treatment is associated with a substantial 50% reduction of death or myocardial infarction in patients with ACS, but it is usually combined with other antiplatelet agents in order to achieve a more profound inhibition of platelet aggregation. Ticlopidine was initially used in association with aspirin in patients treated with percutaneous coronary interventions (PCI), demonstrating a dramatic reduction of the risk of stent thrombosis. Later on it has been replaced by clopidogrel, which now represents in combination with aspirin the standard treatment of patients with ACS treated either medically or invasively, with a 20% risk reduction in comparison with aspirin alone. The limitation of clopidogrel resistance, documented in about 30% of patients because of genetic factors, clinical factors, and pharmacokinetic factors (i.e., poor absorption and drug-drug interactions), has promoted the development of third generation thienopiridines. Prasugrel, which is a more potent and faster inhibitor of platelet aggregation, in comparison with clopidogrel is associated with a further 20% reduction of ischemic events with an increase of major bleedings in patients with ACS undergoing PCI. It is therefore recommended for patients with ACS at high ischemic risk and at non-high hemorrhagic risk. Ticagrelor, a reversible antagonist of P2Y12 platelet receptor, in comparison with clopidogrel is associated with a 16% reduction of ischemic events, including a significant reduction of death from vascular causes, without increasing the rate of overall major bleeding. Intravenous cangrelor, which has been compared with clopidogrel in patients with ACS undergoing PCI, yielded negative results. The use of glycoproteins IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) is no longer recommended as upstream therapy in patients with ACS undergoing PCI, but only in the periprocedural phase. New selective antagonists of thrombin receptor 1 (PAR-1), on top of the standard dual antiplatelet therapy, are now under investigation in patients with ACS and in the secondary prevention. In conclusion, an accurate evaluation is warranted of the balance between ischemic and hemorrhagic risk when deciding the choice of antiplatelet treatment in the individual patient. The hope for the future is the development of new selective platelet inhibitors with higher antischemic efficacy and better hemorrhagic profile." @default.
• W59652332 created "2016-06-24" @default.
• W59652332 creator A5003323114 @default.
• W59652332 creator A5027529869 @default.
• W59652332 creator A5038410102 @default.
• W59652332 creator A5067676269 @default.
• W59652332 creator A5088049432 @default.
• W59652332 creator A5089999932 @default.
• W59652332 date "2010-12-01" @default.
• W59652332 modified "2023-09-24" @default.
• W59652332 title "[Antiplatelet therapy in acute coronary syndromes: state of the art and new perspectives]." @default.
• W59652332 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21491737" @default.
• W59652332 hasPublicationYear "2010" @default.
• W59652332 type Work @default.
• W59652332 sameAs 59652332 @default.
• W59652332 citedByCount "1" @default.
• W59652332 crossrefType "journal-article" @default.
• W59652332 hasAuthorship W59652332A5003323114 @default.
• W59652332 hasAuthorship W59652332A5027529869 @default.
• W59652332 hasAuthorship W59652332A5038410102 @default.
• W59652332 hasAuthorship W59652332A5067676269 @default.
• W59652332 hasAuthorship W59652332A5088049432 @default.
• W59652332 hasAuthorship W59652332A5089999932 @default.
• W59652332 hasConcept C126322002 @default.
• W59652332 hasConcept C164705383 @default.
• W59652332 hasConcept C2776708134 @default.
• W59652332 hasConcept C2777028646 @default.
• W59652332 hasConcept C2777265216 @default.
• W59652332 hasConcept C2777628954 @default.
• W59652332 hasConcept C2777698277 @default.
• W59652332 hasConcept C2777849778 @default.
• W59652332 hasConcept C2778905298 @default.
• W59652332 hasConcept C2780400711 @default.
• W59652332 hasConcept C2780890252 @default.
• W59652332 hasConcept C45393284 @default.
• W59652332 hasConcept C49059817 @default.
• W59652332 hasConcept C500558357 @default.
• W59652332 hasConcept C71924100 @default.
• W59652332 hasConceptScore W59652332C126322002 @default.
• W59652332 hasConceptScore W59652332C164705383 @default.
• W59652332 hasConceptScore W59652332C2776708134 @default.
• W59652332 hasConceptScore W59652332C2777028646 @default.
• W59652332 hasConceptScore W59652332C2777265216 @default.
• W59652332 hasConceptScore W59652332C2777628954 @default.
• W59652332 hasConceptScore W59652332C2777698277 @default.
• W59652332 hasConceptScore W59652332C2777849778 @default.
• W59652332 hasConceptScore W59652332C2778905298 @default.
• W59652332 hasConceptScore W59652332C2780400711 @default.
• W59652332 hasConceptScore W59652332C2780890252 @default.
• W59652332 hasConceptScore W59652332C45393284 @default.
• W59652332 hasConceptScore W59652332C49059817 @default.
• W59652332 hasConceptScore W59652332C500558357 @default.
• W59652332 hasConceptScore W59652332C71924100 @default.
• W59652332 hasIssue "12 Suppl 3" @default.
• W59652332 hasLocation W596523321 @default.
• W59652332 hasOpenAccess W59652332 @default.
• W59652332 hasPrimaryLocation W596523321 @default.
• W59652332 hasRelatedWork W10539617 @default.
• W59652332 hasRelatedWork W1569563801 @default.
• W59652332 hasRelatedWork W1965705149 @default.
• W59652332 hasRelatedWork W1995953692 @default.
• W59652332 hasRelatedWork W2004017808 @default.
• W59652332 hasRelatedWork W2037231610 @default.
• W59652332 hasRelatedWork W2060976579 @default.
• W59652332 hasRelatedWork W2095808364 @default.
• W59652332 hasRelatedWork W2104863471 @default.
• W59652332 hasRelatedWork W2143166891 @default.
• W59652332 hasRelatedWork W2155746465 @default.
• W59652332 hasRelatedWork W2184322685 @default.
• W59652332 hasRelatedWork W2282315526 @default.
• W59652332 hasRelatedWork W2323732684 @default.
• W59652332 hasRelatedWork W2369639111 @default.
• W59652332 hasRelatedWork W2417631447 @default.
• W59652332 hasRelatedWork W2796479226 @default.
• W59652332 hasRelatedWork W2072549250 @default.
• W59652332 hasRelatedWork W2182761039 @default.
• W59652332 hasRelatedWork W2516954016 @default.
• W59652332 hasVolume "11" @default.
• W59652332 isParatext "false" @default.
• W59652332 isRetracted "false" @default.
• W59652332 magId "59652332" @default.
• W59652332 workType "article" @default.